FDA Approves Selarsdi as a Biosimilar Treatment for Psoriasis and Psoriatic Arthritis

FDA Approves Selarsdi as a Treatment Option for Psoriasis and Psoriatic Arthritis

What is Selarsdi?

Selarsdi, manufactured by Alvotech and marketed by Teva, is a biosimilar to Stelara, a medication used to treat psoriasis and psoriatic arthritis. Biosimilars are highly similar to existing medications, but they are developed and manufactured by different companies.

Indications for Selarsdi Treatment

Selarsdi is indicated for the treatment of:

• Moderate to severe plaque psoriasis: Selarsdi can effectively reduce inflammation and relieve symptoms such as itching, redness, and scaling associated with plaque psoriasis.
• Active psoriatic arthritis: Psoriatic arthritis is a chronic inflammatory condition that affects the skin and joints. Selarsdi can help reduce pain, swelling, and stiffness in the joints.
• Psoriasis in pediatric patients six years and older: Selarsdi is also approved for the treatment of plaque psoriasis in children who have not responded to other treatments.

How Does Selarsdi Work?

Similar to Stelara, Selarsdi contains an active ingredient called ustekinumab, which targets the interleukin-12 (IL-12) and interleukin-23 (IL-23) proteins. These proteins play a role in the inflammatory response that leads to psoriasis and psoriatic arthritis. By blocking IL-12 and IL-23, Selarsdi can help reduce inflammation and improve symptoms.

Important Considerations

• Expected Market Launch: Selarsdi is expected to be available in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara.
• Efficacy: Studies have shown that Selarsdi is equally effective as Stelara in treating psoriasis and psoriatic arthritis.
• Dosage and Administration: Selarsdi is administered via subcutaneous injection. The dosage and frequency of administration will vary depending on the patient’s condition and response to treatment.
• Potential Side Effects: Like all medications, Selarsdi carries the potential for side effects. These may include injection site reactions, upper respiratory tract infections, and headache.

Search Query:
What are the conditions treated by Selarsdi, a biosimilar to Stelara?

also read:What Triggers Psoriatic Arthritis Development in Patients with Psoriasis?